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Abstract 
Influenza A virus (IAV) infection is a major public health threat leading to significant morbidity 
and mortality. The emergence of drug-resistant virus strains highlights urgent needs to develop novel 
antiviral drugs with alternative modes of action. Pentagalloyl glucose (PGG), a natural occuring 
polyphenolic compound, possesses broad spectrum of biological activities. In this study, we found 
PGG has anti-influenza virus activity and investigated its possible mechanism(s) of action in vitro. 
Both pre-incubation of virus prior to infection and post-exposure of infected cells with PGG 
significantly inhibited virus yields. Influenza virus-induced hemagglutination of chicken red blood 
cells was inhibited by PGG treatment, suggesting PGG can inhibit IAV infection by interacting with 
viral hemagglutinin. PGG did not affect viral protein synthesis or nuclear transport of viral 
nucleoprotein (NP), but largely reduced plasma membrane accumulation of NP protein at the late stage 
of replication cycle. Furthermore, PGG significantly reduced virus budding and progeny virus release 
from infected cells. Altogether, this study for the first time revealed that PGG can inhibit IAV 
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1. Introduction  
Influenza A virus (IAV) is a segmented, negative sense, single-stranded RNA virus belonging to 
the Orthomyxoviridae family[7]. It causes influenza, which is an acute, highly transmissible respiratory 
infectious disease in humans and animals. Annual seasonal epidemics and occasional pandemics of 
influenza result in significant morbidity and mortality in both humans and animals worldwide. 
Furthermore, the emergence of the highly pathogenic H5N1 avian influenza virus, which was 
associated with a mortality rate in excess of 60% in infected individuals [35], as well as the 2009 flu 
pandemic, a global outbreak of a swine-origin new strain of H1N1 influenza virus, have raised 
significant public health concerns for emergence of a potential novel highly pathogenic pandemic 
influenza [5, 8, 17]. Vaccination is one of the most effective means of prophylactic antiviral therapy, 
while antiviral medications constitute the first line of treatment following infection. Two classes of 
antiviral drugs including M2 channel blockers and neuraminidase inhibitors have proven to be 
clinically effective against influenza. However, due to the high mutation rate of these viruses, the 
emergence of drug-resistant viral strains against both classes of drugs has been reported [22, 36]. This 
highlights the urgent need for discovering novel antiviral drugs with alternative modes of action. 
Recently, evidence is accumulating to show that inhibition of intracellular signaling cascades required 
for virus replication is a novel alternative approach for anti-influenza therapy. The advantage of this 
strategy is that it can avoid the emergence of drug-resistant virus strains due to the fact that the target of 
the drug is a host factor(s) which is not affected by virus mutation [19-21].  
Since many traditional medicinal plants have been reported to have strong antiviral activity [6, 30, 
37], they offer a rich source for discovering novel antiviral compounds. In order to explore novel active 
compounds against IAV, we screened a number of natural compounds purified from different Chinese 
medicinal plants. 1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG), a naturally occurring polyphenolic 
compound abundant in several medicinal plants, was found to exhibit anti-influenza virus activity at 
non-cytotoxic concentrations. A number of in vitro and in vivo studies have previously shown that PGG 
exhibits a wide range of biological activities [41], including anti-inflammatory [16], antioxidant[29], 
anti-angiogenic [25], antitumor [14], antibacterial activity [40], and a broad range of antiviral activity 
against respiratory syncytial virus (RSV) [39], Hepatitis B virus (HBV) [18] and Herpes simplex virus 
(HSV) [27-28, 31]. Moreover, it has been shown to have an inhibitory effect on viral enzymes such as 
integrase and reverse transcriptase of human immunodeficiency virus (HIV-1) [1], and NS3 protease of 
Hepatitis C Virus (HCV) [9]. Although the underlying mechanisms of its antiviral action remains to be 
fully elucidated, the wide spectrum of its antiviral activity against different viruses suggests that PGG 
may target common critical steps in virus-cell interaction rather than a specific viral pathogen.  
In the present study, we investigated the antiviral activity and possible mechanism(s) of action of 
PGG against IAV in vitro. 
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2. Materials and methods 
2.1. Compound 
1,2,3,4,6-penta-O-galloyl-β-D-glucose (PGG) (chemical structure is shown in Fig. 1a) was 
isolated from the branches and leaves of Phyllanthus emblica Linn, and purified as described 
previously [42]. The purity levels achieved were over 98%. PGG was dissolved in dimethyl sulfoxide 
(DMSO) and diluted with culture medium for the following experiments.  
2.2. Cells, viruses and virus infections  
Mardin-Darby canine kidney (MDCK) cells and human alveolar epithelial cell line A549 cells 
were cultured in minimum essential medium (MEM, Invitrogen) and Dulbecco’s modified Eagle’s 
medium (DMEM, Invitrogen), respectively, supplemented with 10% (v/v) fetal bovine serum (FBS, 
Cell Culture Bioscience) and antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). Influenza 
virus strains including A/WSN/33 (H1N1), A/PR8/34 (H1N1) and A/HK/8/68 (H3N2), were 
propagated in 10-day-old embryonated chicken eggs. The allantoic fluids were harvested at 4 days after 
inoculation and stored in the freezer (-80 oC). For virus infections, confluent cells were incubated with 
diluted virus solutions in serum-free medium for 1 hour at 37 oC at the indicated multiplicities of 
infection (MOI). After the adsorption period, the viral inocula were removed and cells were washed 
twice with PBS (-), a Ca2+/Mg2+ free-phosphate buffer solution. The cells were maintained in MEM or 
DMEM (supplemented with 0.5% FBS) containing 0.1% (v/v) DMSO or PGG at the indicated 
concentrations at 37 oC in a humidified 5% CO2 incubator. 0.1% (v/v) DMSO was used as a vehicle 
control. For multiple replication of influenza A/PR8/34 and A/HK/8/68, the medium was additionally 
supplemented with 10µg/ml trypsin (Sigma-Aldrich). 
2.3. WST-1 Assay 
The cytotoxicity and cell-based antiviral activity of PGG were evaluated by Water Soluble 
Tertrazolium-1 (WST-1) assay [15]. For cytotoxicity analyses, confluent MDCK cells in 96-well plates 
(Greiner bio-one) were incubated with serial two-fold dilutions of PGG in MEM. Antiviral activity 
determinations were assessed in parallel. Serial two-fold dilutions of PGG were added to cells, 
followed by the addition of virus inocula of 100 TCID50 (50% tissue culture infective dose) per well. 
After incubation for 72 hours, WST-1 (Dojindo Chemicals) solution (5 mM of WST-1 in 0.2 mM of 
1-methoxy-5-methylphenaziniummethyl sulfate) was added to a final concentration of 0.25 mM. The 
optical density (OD) was measured 4 hours later by scanning at 450nm and 650nm reference 
wavelengths in the Emax precision microplate reader (Molecular Devices). Three independent 
experiments were carried out and each experiment was performed in triplicate. The percentage cell 
viability was compared with untreated controls and plotted against the compound concentration, and 
non-linear regression analysis was performed using Microsoft Excel software to calculate the 50% 
cytotoxic concentration (CC50) and 50% effective concentration (EC50). The selectivity index (SI) for 
PGG was calculated by dividing the CC50 by EC50 (CC50/EC50). 
2.4. Plaque forming unit assay (PFU assay) 
The titers of infectious virus in culture supernatants harvested at the indicated time points were 
determined by PFU assay. Confluent MDCK cells in 6-well dish were infected with serial 10-fold 
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dilutions of the virus in a serum-free medium. After washing twice with PBS (-), cells were overlaid 
with MEM containing 0.8% (w/v) low melting agarose, 0.1% (w/v) BSA, 1% (v/v) vitamins, and 
0.03% (w/v) glutamine. In the case of A/PR8/34 and A/HK/8/68, 10µg/ml trypsin was additionally 
supplemented. After 3 days of incubation, cells were fixed with ethanol: acetic acid (v/v=1:1) for 1 
hour at room temperature and stained with 2.5% (w/v) Amino Black 10B after removal of the 
overlaying agarose gel. The plaques were counted by visual examination. Means and standard 
deviations were calculated from three independent experiments. 
2.5. Time-of-addition assay 
Time-of-addition experiments were performed in which PGG was added at different time intervals 
over a 24-hour incubation period. MDCK cells (6×105 cells/well) were seeded into 12-well plates and 
infected with virus at an MOI of 0.001. PGG (12.5 μg/ml) treatment or DMSO (0.1%, v/v) treatment 
was performed before, during, or after viral infection. At 24 hours post-infection (p.i.), culture 
supernatants of infected cells with different treatment were harvested and the virus titers were 
determined by PFU assay. The detailed procedures of each treatment were carried out as follows: (1) 
Pre-treatment of cells before virus infection: MDCK cells were pre-treated with PGG or DMSO and 
incubated at 37°C for 2 hours. After removal of the pre-treatment medium, the cells were washed twice 
with PBS (-), and infected with influenza virus. At 24 h p.i., cell supernatants were collected and virus 
yields were determined by the PFU assay. (2) Pre-treatment of virus before virus infection. The virus 
(3×103 PFU) was pre-incubated with PGG or DMSO on ice for 1 hour. The mixture of virus and PGG 
or DMSO was then added to MDCK cells, and incubated at 37°C for 1 hour. Cells were then washed 
twice and cultured in fresh medium for 24 hours. (3) Treatment of cells during virus infection. PGG or 
DMSO was administered together with the virus to the cells. After infection, cells were washed twice 
and cultured in fresh medium for 24 hours. (4) Treatment of cells after virus infection. After virus 
infection, cells were treated with PGG or DMSO at the indicated durations (as shown in Fig. 2a) and 
cultured in fresh medium for 24 hours. 
2.6. Western Blotting 
MDCK cells (2×105 cells/well) were seeded into 24-well plates, infected with virus (MOI=1), and 
followed by treatment with PGG (12.5 μg/ml) or DMSO (0.1%, v/v). At 0, 3, 6, 9 and 12 h p.i., cells 
were collected and lysed in sample buffer. An aliquot of 5 μl of each lysate was subjected to 
SDS-PAGE using a 10% separation gel. Proteins were transferred to polyvinylidene fluoride (PVDF) 
membrane (Millipore) for Western blotting analysis, which was performed using mouse monoclonal 
antibodies against NP, HA and M1 proteins of influenza virus A (Santa Cruz Biotech) and α-Tubulin 
(Sigma-Aldrich). Bound antibodies were visualized with an enhanced chemiluminescence (ECL) Plus 
Kit (GE Healthcare Life Sciences). 
2.7 Indirect immunofluorescence microscopy 
MDCK cells were grown on glass coverslips and infected with virus (MOI = 3), and subsequently 
treated with PGG (12.5 μg/ml) or DMSO (0.1%, v/v) after infection. At the indicated time-points p.i., 
cells were fixed with 4% paraformaldehyde (PFA) in PBS for 15 minutes and permeabilized with 
0.02% Triton X-100 in PBS for 15 minutes, and then incubated with anti-NP monoclonal antibody 
6 
(Santa Cruz Biotech) for 1 hour at 37 oC. After washing with PBS, the cells were incubated with the 
goat anti-mouse IgG H & L chain specific biotin conjugate (Calbiochem) for 1 hour at 37 oC. Then 
streptavidin fluorochrome conjugates (Calbiochem) was added to the cells and incubated at 37 oC for 1 
hour. Cell nuclei were counterstained with Hoechst 33342 (Sigma-Aldrich) for 10 minutes at room 
temperature. Slides were examined under fluorescence microscope (Carl Zeiss) using 100× Plan Apo 
objective and the images captured with AxioVision software platform.  
2.8. Transmission Electron Microscopy (TEM) 
MDCK cells were infected with virus (MOI = 3) and treated with PGG (12.5 μg/ml) or DMSO 
(0.1%, v/v) for 12 hours, and then fixed in 3% glutaraldehyde (pH 7.2) for 1.5 hours, and post-fixed in 
1% osmium tetroxide for 1 hour. After dehydration, cells were embedded in Spurr (Sigma-Aldrich). 
Several consecutive ultrathin sections were cut on an LKB Nova ultramicrotome (LKB) and then 
stained with saturated uranyl acetate and lead citrate. These sections were examined under a 
transmission electron microscope, JEM1400 (JEOL). 
2.9. Quantitative real-time RT-PCR 
MDCK cells (2×105 cells/well) were seeded into 24-well plates, and then infected with virus at 
different MOI (1 or 0.01), and followed by treatment with PGG (12.5 μg/ml) or DMSO (0.1%, v/v) for 
12 hours. The culture supernatants were collected from infected cells, after removal of cellular debris 
by centrifugation, total RNA was isolated using PureLinkTM Viral RNA/DNA Kits (Invitrogen) and 
reverse transcribed in the presence of random hexamers using a ReverTra Ace qPCR RT kit (Toyobo). 
The viral genomic segment 7 of influenza A/WSN/33 was specifically amplified by polymerase chain 
reaction (PCR) using the specific primers (sense: TCTGATCCTCTCGTCATTGCAGCAA; antisense: 
AATGACCATCGTCAACATCCACAGC). The cDNA was amplified by PCR using SYBR Green 
Real-time PCR Master Mix (Toyobo), as described by the manufacturer, using ABI PRISM 7000 
Sequence Detection systems. The PCR conditions were as follows: denaturation at 95°C for 1 minute, 
followed by 40 cycles of 95°C for 15 seconds/60°C for 1 minute. Melting curve analysis was 
performed to verify the specificity of the products. A standard curved (R2 >0.99 within the range of 
101-108 copies per reaction) was drawn to convert the respective cycle threshold (Ct) values into the 
number of viral genome copies. This standard consisted of a pCAGGS-WSN-M plasmid construct in 
which was cloned the full sequence of influenza virus A/WSN/33 segment 7. All samples were run in 
triplicate. 
2.10 Hemagglutination inhibition (HI) assay 
HI assay was carried out as described by Christina Ehrhardt et al.[10]. Briefly, serial two-fold 
dilutions of PGG (25µl) were prepared, mixed with equal volume of influenza virus solution (22 of HA 
units/25µl). After incubation of 1h at 4oC, 1% (v/v) of chicken erythrocytes (50µl) in PBS (-) were 
added and incubated for 30 min at room temperature. 
2.11. Statistical analysis 
The results were expressed as mean ± S.E.M. for the three independent experiments. Student’s 
unpaired t-test was used to evaluate the difference between the test samples and untreated controls. A P 
value of <0.01 was considered statistically significant. 
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3. Results 
3.1. Antiviral activity and cytotoxicity of PGG  
For initial analysis of antiviral activity, PGG was tested on MDCK cells in the cell based 
screening assay. And the cytotoxicity of PGG was also evaluated. The EC50 value was 29.59 ± 4.32 
μg/ml (31.48 ± 4.60 μM). No significant cytotoxicity was observed at concentrations of PGG up to 
12.5μg/ml. PGG showed potent inhibitory activity against influenza A/WSN/33(H1N1), the EC50 value 
was 2.36 ± 0.29 μg/ml (2.51 ± 0.31 μM). The selectivity index (SI), which is expressed as the ratio of 
CC50/EC50, was 12.54. 
3.2. Inhibitory effects of PGG on virus yield 
To confirm the inhibitory effects of PGG on virus replication, virus yield was investigated in 
MDCK cells and A549 cells after infection with different strains of influenza A virus in the presence or 
absence of PGG. As shown in Fig. 1b, PGG significantly inhibited influenza A/WSN/33(H1N1) virus 
yields from MDCK cells at 24 and 48 h p.i. in a dose-dependent manner. Maximum reduction (over 4 
log10 PFU/ml) was observed at concentration of 12.5 μg/ml. Comparison with the viral growth kinetics 
of PGG-treated cells and the DMSO-treated cells demonstrated that the inhibitory activity of PGG on 
virus yields remained stable during 48 h p.i. (Fig. 1c). In addition to influenza A/WSN/33(H1N1), PGG 
also inhibited the multiple replication of influenza A/PR8/34 (H1N1) and A/HK/8/68 (H3N2) in 
MDCK cells (Fig 1.d and e). The similar result was also observed in A549 cells instead of MDCK cells. 
Virus yield of A/WSN/33(H1N1) from A549 cells was inhibited under a multiple infection condition in 
the presence of 12.5μg/ml PGG (Fig.1 f). Over 80% of inhibition of virus yield was observed under a 
single infection of A/PR8/34 (H1N1) and A/HK/8/68 (H3N2) (Fig.1 g and h). These data indicated that 
PGG inhibits influenza A virus replication. 
3.3. Mode of action of PGG against influenza A virus 
To investigate the mode of action of PGG, time-of-addition experiments were performed (Fig. 2a). 
Pre-incubation of cells with PGG prior to infection showed no significant inhibitory effect on virus 
yield, however, a significant reductions (over 90%) in virus yield were observed when virus was 
pre-incubated with PGG prior to infection, or cells were treated with PGG during or after infection (Fig. 
2b), suggesting that PGG may have virucidal activity. In order to determine whether PGG inhibited the 
virus yield during a specific period in virus replication cycle, the effect on compound addition at 
different time intervals using MDCK cells was studied. As shown in Fig. 2c, compared to DMSO 
treatment, even when PGG was added 12 hours later after infection, still a more than 95% reduction in 
virus yield was achieved during 24 hours of infection. Furthermore, to avoid an exposure of newly 
formed virions to PGG prior to titration, infected cells were exposed to PGG only within a single 
replication cycle (0-12 hours post-infection), and then the supernatants containing PGG or DMSO were 
replaced with fresh medium. As shown in Fig. 2d, in comparison to DMSO treatment, PGG treatment 
do not affect virus yield during the first 3 hours of treatment (0-3 hours), however, a significant 
reduction in virus yield was observed at 0-6 hours. Similarly, at 0-9 hours and 0-12 hours, the efficacy 
of inhibition reached 86% and 94%, respectively (Fig.2d). These results implicated that PGG may 
interfere predominantly with the late stage of the virus replication cycle independent of its viricidal 
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activity. 
3.4. Inhibitory effects of PGG on hemagglutination 
Since influenza A viruses are able to agglutinate chicken red blood cells (RBCs) by binding of 
their viral envelope spike protein hemagglutinin (HA) to the receptors on RBCs, to further confirm the 
effect of PGG on virus adsorption to cells, a hemagglutination inhibition assay was carried out. As 
shown in Table.1, PGG inhibited HA activity for all the three virus strains in a concentration dependent 
manner. These results suggested that PGG is capable of directly interacting with the viral glycoprotein 
HAs to block virus adsorption to cells. 
3.5. Effects of PGG on viral protein synthesis  
To confirm whether the inhibitory effects of PGG treatment on viral replication were related to the 
production of viral proteins, the expressions of viral proteins of infected cells, which were treated with 
PGG for 3, 6, 9 or 12 hours, were analyzed by Western blotting. As shown in Fig. 3, in which the viral 
protein levels were normalized by -tubulin, PGG did not significantly affect the expressions of viral 
HA, NP and M1 proteins.  
3.6. Effects of PGG on distribution of viral nucleoprotein (NP) in MDCK cells 
To evaluate the effect of PGG on intracellular trafficking of virus ribonucleoprotein (NP), indirect 
immunofluorescence staining was performed using anti-NP antibody at 3, 6, 9, and 12 h p.i.. As shown 
in Fig. 4, viral NP accumulated in the nucleus of infected cells as early as 3 h p.i. (Fig. 4a and 4c), and 
translocation to the cytoplasm was completed within 9 h p.i. (Fig. 4i and 4k). No difference in the 
distribution pattern of NP was observed between PGG-treated and untreated cells until 6 h p.i.. The 
viral NP accumulated at the leading edge of cells without PGG treatment (Fig. 4i and 4m, arrow), but 
not in the PGG-treated cells at 9 and 12 h p.i. (Fig. 4k and 4o). These results indicated that PGG did not 
affect nuclear entry, or extranuclear translocation of NP at the early and middle stages of the replication 
cycle (0 to 6 hours), but interfered with the accumulation of NP on the surface of the cell membrane at 
the late stage of the replication cycle (9 to 12 hours).  
3.7. Ultrastructural analysis of virus budding by TEM 
Ultrastructural analysis of cells by TEM showed that most of the mock-infected cells were 
smooth-surfaced, or had sparsely scattered microvillar membrane protrusions (Fig. 5a and 5d). In 
contrast, many membrane protrusions were observed on the surface of infected cells that had not been 
treated with PGG (Fig. 5b and 5e), in which there were numerous budding viral particles (arrows) on 
the surface of the microvillar protrusions (Fig. 5g). PGG treatment reduced the appearance of 
microvillar protrusions on the surface of cells (Fig. 5c), and decreased budding virus particles (arrows), 
in which virus buds are seen lining the surface of the cell membrane (Fig. 5f). Virus buds exhibited a 
spherical shape rather than an elongated or filamentous form (Fig. 5h). These results revealed that PGG 
possibly affects the surface structure of the plasma membrane which may causes the reduction in virus 
assembly and budding on the surface of infected cells.  
3.8. Effects of PGG on virus particle release  
To confirm whether the release of total virus particles from infected cells was suppressed by PGG, 
we treated the infected cells with PGG within the first replication cycle (5h or 8h upon infection) and 
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determined the virus titers at 12h post-infection. As shown in Fig. 6 a and b, in comparison to DMSO 
treatment, treatment of PGG for 5h or 8h upon infection significantly inhibited the virus titer (over 90% 
reduction). We further analyzed the copy number of viral genomic RNA in the supernatants from 
infected cells at 12 h p.i. using quantitative real-time RT-PCR. A more than 70% of reduction in the 
amount of viral genomic RNA was observed in the culture supernatants in the presence of PGG (Fig. 6 





In the present study, our results indicate that PGG isolated from Phyllanthus emblica Linn 
effectively inhibits influenza A virus replication via two mechanisms: prevention of virus adsorption 
and suppression of virus release. Pre-treatment of virus before infection or treatment of cells during 
infection largely reduced virus yields during 24 hours of infection, however, pre-treatment of cells prior 
to infection did not significantly reduced virus yield, in addition, the early three hours of PGG 
treatment after infection did not affect on virus yield. Thereby, it is conceivable that the inhibitory 
effect of PGG was mainly caused by the direct interaction of PGG with virus. Numerous studies have 
demonstrated that plant polyphenols including the tea catechins (-) epigallocatechin gallate (EGCG) 
and theaflavin digallate [34], resveratrol (RV) [26], a polyphenol rich extract (CYSTUS052) [11], 
pomegranate polyphenol extract (PPE) [13] , oligonol[12], and Hydroxytyrosol (HT) [38], have potent 
antiviral activity against influenza virus, that are related to the nature of their interactions with viral 
particles. Additionally, indirect effects of some polyphenols, such as EGCG and strictinin, on host cells 
that might interfere with virus-cell membrane fusion have also been suggested [23, 32]. In this study, 
our results demonstrated that PGG inhibits virus-induced hemagglutination of chicken red blood cells, 
suggesting that PGG can interact with virus particles. Analysis of the detailed mechanisms of PGG 
acting on viral HA is currently underway. 
Notably, our results also showed that PGG can reduce virus yields at the late stage of replication 
cycle independent of its virucidal activity. This effect has been suported by the results that virus release 
significantly reduced by PGG treatment in a single virus replication cycle. Reduced release of virus 
particles was evident in the results of four independent assays: (i) lower virus titers as determined by 
PFU assay, (ii) reduced membrane accumulation of NP protein as determined by immunofluorescence 
staining, (iii) decreased numbers of virus particles on the surface of plasma membrane as determined 
by TEM observation, and (iv) reduced viral genomic RNA in culture supernatants as determined by 
quantative realtime RT-PCR. Both treatment of PGG for 5h and 8h upon infection significantly 
inhibited virus release, suggesting that PGG may interfere with the steps before virus release in late 
stage of replication cycle. PGG treatment did not affect the expressions of viral proteins in infected 
cells and the nuclear transport of viral NP protein, but the accumulation of NP on plasma membrane 
was significantly suppressed in the presence of PGG, which was accordance with the reduction of virus 
buds on plasma membrane in the presence of PGG in TEM study. In addition, PGG treatment induced 
reduction of microvilli-like membrane protrusions, which is the site for virus assembly and budding. It 
is likely that PGG acts on the cellular membrane and therefore interferes with virus budding and 
release.  
Influenza virus budding and release are essential for the transmission of the virus and in the 
pathogenesis of disease. A better understanding of these processes will help us in identifying new 
targets for prevention of influenza virus infection. Disruption of actin microfilaments by inhibitors 
alters the distribution of NP at the apical plasma membrane [33]. Influenza virus NP protein is known 
to associate with the actin cytoskeleton which may provide the pushing force for incorporating the 
vRNP complex into the bud [2], also vRNPs can be directed to the apical budding site via its 
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association with lipid rafts [4]. Although the molecular mechanism of transport of vRNPs to apical 
plasma membrane remains to be fully elucidated, recently, the Rab11-mediated membrane trafficking 
pathway has been reported to be required for IAV budding [3]. We have recently reported that PGG can 
down-regulate cofilin1, a key regulator of actin cytoskeleton dynamics, which might be associated with 
its anti-HSV-1 activity [28]. Whether these cellular factors as common targets were affected by PGG 
treatment needs be further examinated. Moreover, virus particles release from the surface of plasma 
membrane in the late stage of influenza virus replication requires the envelope spike glycoprotein 
neuraminidase (NA) that has sialidase activity [24]. The inhibition of virus release by PGG treatment 
whether associated with the effect of PGG on NA activity also seem to be an intriguing subject.  
In conclusion, this study for the first time demonstrated that PGG possesses antiviral activity 
against influenza A virus in vitro. PGG inhibits productive replication of IAV not only by inhibiting 
virus infection but also by interfering with virus budding and release. The dual mode of action of PGG 




This work was supported by Grant-in-aid from the Tokyo Biochemical Research Foundation, and 
was partially supported by the Joint Funds of National Science Foundation of China (U0632010), the 
State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of 




1. Ahn MJ, Kim CY, Lee JS, Kim TG, Kim SH, Lee CK, Lee BB, Shin CG, Huh H, Kim J (2002) 
Inhibition of HIV-1 integrase by galloyl glucoses from Terminalia chebula and flavonol glycoside 
gallates from Euphorbia pekinensis. Planta Med 68:457-459 
2. Avalos RT, Yu Z, Nayak DP (1997) Association of influenza virus NP and M1 proteins with 
cellular cytoskeletal elements in influenza virus-infected cells. J Virol 71:2947-2958 
3. Bruce EA, Digard P, Stuart AD (2010) The Rab11 pathway is required for influenza a virus 
budding and filament formation. J Virol 84:5848-5859 
4. Carrasco M, Amorim MJ, Digard P (2004) Lipid raft-dependent targeting of the influenza A virus 
nucleoprotein to the apical plasma membrane. Traffic 5:979-992 
5. CDC (2009) Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. 
MMWR Morb Mortal Wkly Rep 58:453-458 
6. Chuanasa T, Phromjai J, Lipipun V, Likhitwitayawuid K, Suzuki M, Pramyothin P, Hattori M, 
Shiraki K (2008) Anti-herpes simplex virus (HSV-1) activity of oxyresveratrol derived from Thai 
medicinal plant: mechanism of action and therapeutic efficacy on cutaneous HSV-1 infection in 
mice. Antiviral Res 80:62-70 
7. David M Knipe PMH, Diane E Griffin, Robert A Lamb, Malcolm A Martin (2007)  Fields 
Virology. Lippincott Williams and Wilkins, New York, pp 1647-1689 
8. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, Gubareva LV, Xu X, Bridges 
CB, Uyeki TM (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N 
Engl J Med 360:2605-2615 
9. Duan D, Li Z, Luo H, Zhang W, Chen L, Xu X (2004) Antiviral compounds from traditional 
Chinese medicines Galla Chinese as inhibitors of HCV NS3 protease. Bioorg Med Chem Lett 
14:6041-6044 
10. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, 
Planz O, Ludwig S (2007) A polyphenol rich plant extract, CYSTUS052, exerts anti influenza 
virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. 
Antiviral Research 76:38-47 
11. Ehrhardt C, Hrincius ER, Korte V, Mazur I, Droebner K, Poetter A, Dreschers S, Schmolke M, 
Planz O, Ludwig S (2007) A polyphenol rich plant extract, CYSTUS052, exerts anti influenza 
virus activity in cell culture without toxic side effects or the tendency to induce viral resistance. 
Antiviral Res 76:38-47 
12. Gangehei L, Ali M, Zhang W, Chen Z, Wakame K, Haidari M (2010) Oligonol a low molecular 
weight polyphenol of lychee fruit extract inhibits proliferation of influenza virus by blocking 
reactive oxygen species-dependent ERK phosphorylation. Phytomedicine 17:1047-1056 
13. Haidari M, Ali M, Ward Casscells S, 3rd, Madjid M (2009) Pomegranate (Punica granatum) 
purified polyphenol extract inhibits influenza virus and has a synergistic effect with oseltamivir. 
Phytomedicine 16:1127-1136 
14. Huh JE, Lee EO, Kim MS, Kang KS, Kim CH, Cha BC, Surh YJ, Kim SH (2005) 
Penta-O-galloyl-beta-D-glucose suppresses tumor growth via inhibition of angiogenesis and 
stimulation of apoptosis: roles of cyclooxygenase-2 and mitogen-activated protein kinase 
pathways. Carcinogenesis 26:1436-1445 
15. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K (1996) A combined assay of 
13 
cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and 
crystal violet. Biol Pharm Bull 19:1518-1520 
16. Kang DG, Moon MK, Choi DH, Lee JK, Kwon TO, Lee HS (2005) Vasodilatory and 
anti-inflammatory effects of the 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) via a nitric 
oxide-cGMP pathway. Eur J Pharmacol 524:111-119 
17. Korteweg C, Gu J (2010) Pandemic influenza A (H1N1) virus infection and avian influenza A 
(H5N1) virus infection: a comparative analysis. Biochem Cell Biol 88:575-587 
18. Lee SJ, Lee HK, Jung MK, Mar W (2006) In vitro antiviral activity of 
1,2,3,4,6-penta-O-galloyl-beta-D-glucose against hepatitis B virus. Biol Pharm Bull 29:2131-2134 
19. Lu X, Masic A, Li Y, Shin Y, Liu Q, Zhou Y (2010) The PI3K/Akt pathway inhibits influenza A 
virus-induced Bax-mediated apoptosis by negatively regulating the JNK pathway via ASK1. J Gen 
Virol 91:1439-1449 
20. Ludwig S, Wolff T, Ehrhardt C, Wurzer WJ, Reinhardt J, Planz O, Pleschka S (2004) MEK 
inhibition impairs influenza B virus propagation without emergence of resistant variants. FEBS 
Lett 561:37-43 
21. Mazur I, Wurzer WJ, Ehrhardt C, Pleschka S, Puthavathana P, Silberzahn T, Wolff T, Planz O, 
Ludwig S (2007) Acetylsalicylic acid (ASA) blocks influenza virus propagation via its 
NF-kappaB-inhibiting activity. Cell Microbiol 9:1683-1694 
22. Moscona A (2008) Medical management of influenza infection. Annu Rev Med 59:397-413 
23. Nakayama M, Suzuki K, Toda M, Okubo S, Hara Y, Shimamura T (1993) Inhibition of the 
infectivity of influenza virus by tea polyphenols. Antiviral Res 21:289-299 
24. Nayak DP, Balogun RA, Yamada H, Zhou ZH, Barman S (2009) Influenza virus morphogenesis 
and budding. Virus Res 143:147-161 
25. Oh GS, Pae HO, Choi BM, Lee HS, Kim IK, Yun YG, Kim JD, Chung HT (2004) 
Penta-O-galloyl-beta-D-glucose inhibits phorbol myristate acetate-induced interleukin-8 
[correction of intereukin-8] gene expression in human monocytic U937 cells through its 
inactivation of nuclear factor-kappaB. Int Immunopharmacol 4:377-386 
26. Palamara AT, Nencioni L, Aquilano K, De Chiara G, Hernandez L, Cozzolino F, Ciriolo MR, 
Garaci E (2005) Inhibition of influenza A virus replication by resveratrol. J Infect Dis 
191:1719-1729 
27. Pei Y, Chen ZP, Ju HQ, Komatsu M, Ji YH, Liu G, Guo CW, Zhang YJ, Yang CR, Wang YF, 
Kitazato K (2011) Autophagy is involved in anti-viral activity of pentagalloylglucose (PGG) 
against Herpes simplex virus type 1 infection in vitro. Biochem Biophys Res Commun 
405:186-191 
28. Pei Y, Xiang YF, Chen JN, Lu CH, Hao J, Du Q, Lai CC, Qu C, Li S, Ju HQ, Ren Z, Liu QY, 
Xiong S, Qian CW, Zeng FL, Zhang PZ, Yang CR, Zhang YJ, Xu J, Kitazato K, Wang YF (2011) 
Pentagalloylglucose downregulates cofilin1 and inhibits HSV-1 infection. Antiviral Res 89:98-108 
29. Piao X, Piao XL, Kim HY, Cho EJ (2008) Antioxidative activity of geranium (Pelargonium 
inquinans Ait) and its active component, 1,2,3,4,6-penta-O-galloyl-beta-D-glucose. Phytother Res 
22:534-538 
30. Pleschka S, Stein M, Schoop R, Hudson JB (2009) Anti-viral properties and mode of action of 
standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, 
H7N7) and swine-origin H1N1 (S-OIV). Virol J 6:197 
31. Quideau S, Varadinova T, Karagiozova D, Jourdes M, Pardon P, Baudry C, Genova P, Diakov T, 
14 
Petrova R (2004) Main structural and stereochemical aspects of the antiherpetic activity of 
nonahydroxyterphenoyl-containing C-glycosidic ellagitannins. Chem Biodivers 1:247-258 
32. Saha RK, Takahashi T, Kurebayashi Y, Fukushima K, Minami A, Kinbara N, Ichitani M, Sagesaka 
YM, Suzuki T (2010) Antiviral effect of strictinin on influenza virus replication. Antiviral Res 
88:10-18 
33. Simpson-Holley M, Ellis D, Fisher D, Elton D, McCauley J, Digard P (2002) A functional link 
between the actin cytoskeleton and lipid rafts during budding of filamentous influenza virions. 
Virology 301:212-225 
34. Song JM, Lee KH, Seong BL (2005) Antiviral effect of catechins in green tea on influenza virus. 
Antiviral Res 68:66-74 
35. Uyeki TM (2009) Human infection with highly pathogenic avian influenza A (H5N1) virus: 
review of clinical issues. Clin Infect Dis 49:279-290 
36. Vicente D, Cilla G, Montes M, Mendiola J, Perez-Trallero E (2009) Rapid spread of drug-resistant 
influenza A viruses in the Basque Country, northern Spain, 2000-1 to 2008-9. Euro Surveill 14 
37. Wang X, Jia W, Zhao A (2006) Anti-influenza agents from plants and traditional Chinese medicine. 
Phytother Res 20:335-341 
38. Yamada K, Ogawa H, Hara A, Yoshida Y, Yonezawa Y, Karibe K, Nghia VB, Yoshimura H, 
Yamamoto Y, Yamada M, Nakamura K, Imai K (2009) Mechanism of the antiviral effect of 
hydroxytyrosol on influenza virus appears to involve morphological change of the virus. Antiviral 
Res 83:35-44 
39. Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ, Lee HJ, Park HK, Kook YH (2002) 
Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial 
cells. Arch Virol 147:229-242 
40. Zhang F, Luo SY, Ye YB, Zhao WH, Sun XG, Wang ZQ, Li R, Sun YH, Tian WX, Zhang YX 
(2008) The antibacterial efficacy of an aceraceous plant [Shantung maple (Acer truncatum 
Bunge)] may be related to inhibition of bacterial beta-oxoacyl-acyl carrier protein reductase 
(FabG). Biotechnol Appl Biochem 51:73-78 
41. Zhang J, Li L, Kim SH, Hagerman AE, Lu J (2009) Anti-Cancer, Anti-Diabetic and Other 
Pharmacologic and Biological Activities of Penta-Galloyl-Glucose. Pharm Res 26:2066-2080. 
42. Zhang Y-J, Nagao T, Tanaka T, Yang C-R, Okabe H, Kouno I (2004) Antiproliferative Activity of 







Fig.1 Inhibitory effects of PGG on viral yields. (a) Chemical structure of 1,2,3,4,6-penta-O-galloyl- β- 
D-glucose (PGG). (b) Dose-course of PGG treatment (1.56 to 12.5g/ml) on virus titers. MDCK cells 
were infected with A/WSN/33 (MOI = 0.001), subsequently treated with serial 2-fold dilutions of PGG 
or 0.1% (v/v) of DMSO, culture supernatants were harvested at 24 and 48 hours post infection (p.i.), 
and virus titers were determined by plaque assay. (c) Growth kinetics of A/WSN/33 virus in MDCK 
cells. Cells were infected with A/WSN/33 virus (MOI = 0.001), and subsequently treated with PGG 
(6.25 and 12.5g/ml) or DMSO (0.1%,v/v). Virus yields were determined at 8, 24, 36, 48h p.i.. (d) 
Effect of PGG on multiple replication of A/WSN/33 virus in A549 cells. Cells were infected with 
A/WSN/33 virus (MOI=0.01), and subsequently treated with PGG (12.5g/ml) or 0.1% (v/v) of DMSO, 
virus yields was determined at 8 and 24h p.i.. (e) and (f) Effect of PGG on single step replication of 
A/PR8/34 and A/HK/8/68 virus in A549 cells. Cells were infected with A/PR8/34 virus and A/HK/8/68 
virus (MOI=1), and subsequently treated with PGG (6.25 and 12.5g/ml) or 0.1% (v/v) of DMSO, 
virus yields were determined at 8h p.i.. Values represent the mean of PFU/ml from three independent 
experiments and error bars show the standard deviation of the mean. The asterisks indicate significant 
difference between PGG and DMSO treatment, *P < 0.01. 
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Fig. 2 Mode of action of PGG against influenza A virus. MDCK cells were infected with A/WSN/33 
(MOI = 0.001) and treated with PGG (12.5 μg/ml) or 0.1% (v/v) DMSO (the control). The culture 
supernatant was collected at 24h post-infection, and virus yields were determined by plaque assay. (a) 
Different PGG treatment protocols. (b) PGG was added to cells before, during or after virus infection, 
or virus was pre-incubated with PGG prior to infection. (c) PGG was added to cells after virus infection 
at different time points (3h, 6h, 9h and 12h p.i). (d) Infected cells were exposure to PGG at different 
period time after infection (0-3h, 0-6h, 0-9h, 0-12h and 0-24h p.i). The virus titers from the 
PGG-treated cells were presented as a percentage of the control (treatment of DMSO (0.1%, v/v)). 
Values represent the mean of three independent experiments, and error bars show the standard 
deviation of the mean. The asterisks indicate significant differences between DMSO and PGG 




Fig. 3 Effects of PGG on viral protein synthesis. MDCK cells were infected with A/WSN/33 (MOI=1) 
and subsequently treated with 12.5 μg/ml PGG or 0.1% (v/v) DMSO for 12 hours after infection. At 0, 
3, 6, 9 and 12 hours post-infection, cells were lyzed and subjected to Western blot analysis using 
monoclonal antibody against influenza A HA, NP and M1 proteins and anti-α-tubulin antibody(a). 
Protein band densities were quantified using Image J software. The relative levels of virus HA (b), NP 




Fig. 4 Effects of PGG on subcellular distribution of viral nucleoprotein. MDCK cells were infected 
with A/WSN/33 (MOI = 3), and subsequently treated with 12.5 μg/ml PGG or 0.1% (v/v) DMSO after 
infection. Cells were fixed and immunofluorescence stained at 3 hours (a to d), 6 hours (e to h), 9 hours 
(i to l), and 12 hours (m to p) and analyzed by fluorescence microscopy. Cells were co-stained with 
anti-NP antibody (Alexa 546: Red) (a, c, e, g, i, k, m, o), and Hoechst 33342 (Blue) (b, d, f, h, j, l, n, p). 




Fig. 5 Ultrastructure of virus budding on cell surface. MDCK cells were infected with influenza 
A/WSN/33 virus (MOI = 3), and subsequently treated with 12.5μg/ml PGG or 0.1% (v/v) of DMSO for 
12 hours. Cells were examined with a TEM as described in Materials and Methods. The figure depicts 
mock-treated cells (a, d), infected cells treated with DMSO (b, e, g), and infected cells treated with 
PGG (c, f, h). Boxed areas with the dotted line are shown at a higher magnification in d, e and f. g and 
h represent the enlarged image of boxed areas with full lines in e and f, respectively. Arrows illustrate 




Fig. 6 Effects of PGG on viral particle release. (a) Inhibitory effects of PGG on virus titer. MDCK cells 
were infected with A/WSN/33 (MOI=1 and MOI=0.01), and treated with 12.5 μg/ml PGG or 0.1% (v/v) 
of DMSO for 5h or 8h upon infection. Virus titer of culture supernatant was determined at 12h 
post-infection. (b) Effects of PGG on the amount of viral RNAs in culture supernatant. MDCK cells 
were infected with A/WSN/33 (MOI=1, and MOI=0.01), and treated with 12.5 μg/ml PGG or 0.1% 
(v/v) of DMSO for 12 hours. Viral genomic RNA (segment 7) in culture supernatant was analyzed 
using quantitatively real-time RT-PCR. Viral RNAs in cell culture supernatants from PGG-treated cells 
were compared to the control (treatment with DMSO). Values represent the mean of three independent 
experiments, and error bars show the standard deviation of the mean. The asterisks indicate significant 
differences between DMSO and PGG treatment, *P < 0.01. 
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